# pipeline

## ADVANCING A PIPELINE BUILT ON PRECISION

We’re advancing a pipeline built on precision, where each program teaches the next, and every success compounds value.

## the pathos development model: A Smarter System for Clinical Progress

### Traditional pipelines progress in phases. Ours accelerates through engines that learn.

### Each trial within the PathOS™ platform integrates multimodal data and adaptive AI to refine patient selection, optimize design, and accelerate clinical outcomes.

#### data-informed

#### AI-Enabled

#### Clinically Proven

[Explore the pathos platform](https://www.pathos.com/platform-old)

## programs in development

preclinical

phase 1

phase 2

phase 3

* * *

### Pocenbrodib (CBP/P300 inhibitor)

Indication: Prostate, Breast, Multiple Myeloma

##### Additional Information

Pocenbrodib (previously FT-7051) is a small molecule inhibitor that has the potential to provide clinical benefit for patients with advanced prostate cancer, either alone or in combination with other treatments.

Pocenbrodib works by inhibiting CREBBP/EP300 (also known as CBP/P300), which are proteins that activate genes that promote cancer cell growth and proliferation.

### P-500 (PRMT5i)

Indication: Solid Tumors

##### Additional Information

P-500 (previously PRT811) is a selective, brain-penetrant small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) that has the potential to provide clinical benefit for patients with advanced solid tumors, including high-grade glioma and uveal melanoma.

*Pathos integrates patient selection data, mechanistic modeling, and trial intelligence into each program — creating a self-improving system that drives both scientific and commercial success.*

## The Science Behind Data-Driven Discovery

Our translational research connects molecular mechanisms to real-world outcomes. Pathos collaborates with leading oncology institutions to publish, validate, and refine its platform across tumor types and therapeutic classes.

* * *

Abstract 6249: Probabilistic causal network models from real-world prostate cancer data identify potential synergistic combinations with CBP/P300 inhibitors.

FT-6876, A Potent and Selective Inhibitor of CBP/p300 with Antitumor Activity in AR-Positive Breast Cancer.

The Courage Study: A First-In-Human Phase 1 Study of the CBP/p300 Inhibitor FT-7051 in Men With Metastatic Castration-Resistant Prostate Cancer.

### Learn more about the Pathos Platform

Each program teaches the next, advancing a repeatable model for precision drug development that compounds over time.